Recursion is investing a large portion of their efforts on advancing the development of their product candidates all the way until commercialization, which in my opinion is slowing down the evolution ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference. The trial met its primary ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...